Responses
Clinical/translational cancer immunotherapy
Original research
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.